
Novo Nordisk will most likely not lose sales in China in the event of a Danish re-evaluation of reimbursements for the company’s diabetes drugs Victoza and Levemir, which will only be given conditional reimbursements if the proposal is approved.
That is the unanimous opinion of the analysts interviewed by Danish newspaper Berlingske.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app